Willis Johnson & Associates’s DexCom DXCM Stock Holding History

Willis Johnson & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,880	Closed	-$266K	–	92
2020 Q4	$266K	Buy	+2,880	New	+$257K	0.04%	71

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Willis Johnson & Associates's DXCM Position: Q1 2021 in Review

Willis Johnson & Associates sold out of DexCom (DXCM) in Q1 2021, closing a stake of 2,880 shares — an estimated $266K sold.

Willis Johnson & Associates first reported a position in DXCM in Q4 2020 and held it in 1 quarter. The position peaked at $266K in Q4 2020. 729 funds tracked by Wall St. Rank hold DXCM as of Q1 2021.

Willis Johnson & Associates reported no remaining DexCom position as of Q1 2021 after selling out during the quarter.
Willis Johnson & Associates sold 2,880 DexCom shares in Q1 2021, an estimated $266K.
Willis Johnson & Associates first reported a position in DexCom in Q4 2020 and held it in 1 quarter.
Willis Johnson & Associates's DexCom position peaked at $266K in Q4 2020.
729 funds tracked by Wall St. Rank held DexCom as of Q1 2021.

Based on Willis Johnson & Associates's 13F filing for Q1 2021, filed 29 Apr 2021.